首页|子宫颈癌十年研究回顾

子宫颈癌十年研究回顾

扫码查看
子宫颈癌是一种病因明确且可防可控的恶性肿瘤.尽管人乳头瘤病毒(human papillomavirus,HPV)疫苗研发和子宫颈癌筛查已广泛开展,但其发病率仍逐年上升,并呈现低龄化的趋势,提示子宫颈癌防控仍有待优化.因此世界卫生组织提出加速消除子宫颈癌全球战略.随着对HPV致癌机制的深入研究,子宫颈癌筛查技术不断革新,出现HPV拓展分型、p16INK4a(p16)/Ki-67 双重染色(双染)、基因甲基化和HPV整合检测等具有临床前景的新技术.另外,为改善子宫颈癌患者的预后,基于新辅助化疗、同步放化疗、免疫治疗和靶向治疗等不同治疗方式的联合方案成为临床研究热点.本文就子宫颈癌 10 年研究现状进行述评.
Ten-year review of cervical cancer study
Cervical cancer is a malignant tumor with clear etiology and prevention strategy.Although human papillomavirus(HPV)vac-cination and cervical cancer screening have been widely carried out,the incidence of cervical cancer is still rising year by year and showing a trend of younger age.It suggests that the prevention and control of cervical cancer still needs to be improved.Thus,the World Health Organization proposed a global strategy to accelerate the elimination of cervical cancer.With the in-depth study of HPV carcinogenesis,the cervical cancer screening technology continues to innovate.Some new technologies have emerged in recent years,such as extended HPV genotyping,p16INK4a(p16)/Ki-67 dual stain,gene methylation and HPV integration detection.In addition,in order to improve the prog-nosis of patients with cervical cancer,the combinations of neoadjuvant chemotherapy,concurrent chemoradiotherapy,immunotherapy and targeted therapy have become research hotspots.This manuscript reviews the research of cervical cancer in the past ten years.

cervical cancerhuman papillomavirus vaccinationprimary human papillomavirus-based screeningtargeted therapyimmunotherapy

李晓、吕卫国

展开 >

浙江大学医学院附属妇产科医院妇科肿瘤科,浙江省妇产疾病临床医学研究中心,浙江杭州 310006

子宫颈癌 人乳头瘤病毒疫苗 人乳头瘤病毒初筛 靶向治疗 免疫治疗

浙江省尖兵领雁重点研发计划浙江省教育厅科研项目

2023C03169Y202249960

2024

实用肿瘤杂志
浙江大学

实用肿瘤杂志

CSTPCD
影响因子:1.034
ISSN:1001-1692
年,卷(期):2024.39(4)